Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai to market and distribute Belviq weight management therapy in US
Indicated for people with body mass index (BMI) of 30kg/m2 or more, or BMI of 27kg/m2 or more and coupled with a minimum of one weight-related medical condition
Indicated for people with body mass index (BMI) of 30kg/m2 or more, or BMI of 27kg/m2 or more and coupled with a minimum of one weight-related medical condition
The investigational product is an oral nucleotide analogue inhibitor to be administered once each day with the safety and efficacy profile yet to be evaluated. Under the Prescription
Backed by PA Consulting-developed social media analysis software, the patient recruitment program will enable users’ to access new information about potential patients, including mapping the geographical distribution of
AB SCIEX Triple Quad 6500 LC-MS/MS Systems are designed to facilitate higher levels of sensitivity and increased limits of quantitation to its bioanalytical services in support of pharmacokinetic
The collaboration will leverage CytomX’s Probody Platform to develop safe and effective antibody-drug conjugates (ADCs). CytomX chief executive officer Sean McCarthy said, "Combining our novel Probody Platform with
Designed to lessen attrition rates and improve the ranking of early drug candidates, the new system comprises both manufacturability and safety assessments for early detection of possible chemical/physical
Produced in Unit 2 of Rafarma’s Terbuni plant, Ceftriaxone formulated for injections will be packed in 10ml bottles with single gram dosages. With an estimated Ceftriaxone market of
Initial customers have already adopted the system to characterize CTCs for biomarkers such as gene expression, mutations, and chromosomal aberrations. Designed for high sensitivity enrichment of rare cells
Composition of a series of prodrugs activated by HK2 enzyme to deliver a thapsigargin derivative selectively targeting prostate cancers is protected by the patent. GenSpera CEO Craig Dionne
Scheduled to commence operations early in 2016, the new facility will be the first to use mammalian cell culture technology in the production of biopharmaceuticals in China. Set